Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes Management
Diabetes Medication and Drugs
Insulin
Toujeo insulin
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="tim2000s" data-source="post: 1377568" data-attributes="member: 30007"><p>[USER=226641]@flashgordon12345[/USER] - The reason that Sanofi had to introduce Toujeo was that Lantus has reached the end of its patent, which means that biosimilar competitors could join the market. Basaglar is this insulin. The idea is that biosimilars should be cheaper, so companies opt to produce a new or modified version of their own product in order to continue to make profits. That's what Toujeo is in this context. </p><p></p><p>In terms of its performance in the field, it appears to have better variance and fewer hypos than Lantus/NPH, but those are Sanofi run trials. </p><p></p><p>[USER=202581]@asparagusp[/USER], I'm not sure that I'd call that insulin. It's clearly a dual-factor concoction using insulin and a GLP-1 incretin , meaning that aside from adding insulin, it also reduces the production of Glucagon and stimulates Beta cells.</p></blockquote><p></p>
[QUOTE="tim2000s, post: 1377568, member: 30007"] [USER=226641]@flashgordon12345[/USER] - The reason that Sanofi had to introduce Toujeo was that Lantus has reached the end of its patent, which means that biosimilar competitors could join the market. Basaglar is this insulin. The idea is that biosimilars should be cheaper, so companies opt to produce a new or modified version of their own product in order to continue to make profits. That's what Toujeo is in this context. In terms of its performance in the field, it appears to have better variance and fewer hypos than Lantus/NPH, but those are Sanofi run trials. [USER=202581]@asparagusp[/USER], I'm not sure that I'd call that insulin. It's clearly a dual-factor concoction using insulin and a GLP-1 incretin , meaning that aside from adding insulin, it also reduces the production of Glucagon and stimulates Beta cells. [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes Management
Diabetes Medication and Drugs
Insulin
Toujeo insulin
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…